Register for our free email digests:
Vantia Therapeutics Ltd.
www.vantiatherapeutics.com
Latest From Vantia Therapeutics Ltd.
Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
Royalty Rights To AMD Drug Spur $175 Million Capital Raise For Ophthotech
Money will finance 1,900-patient, 200-site Phase III trial for wet AMD drug Fovista, expected to work in concert with anti-VEGF therapies such as Lucentis to restore eye function. The transaction is just the latest ophthalmology financing involving Novo AS, SV Life Sciences and executives once with Eyetech.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gastrointestinal
- Respiratory, Pulmonary
- Alias(es)
- Vantia Ltd.
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Vantia Therapeutics Ltd.
- Senior Management
-
Andrew Crockett, CEO
Stephen Donnelly, CFO
Robert Haigh, PhD, CSO - Contact Info
-
Vantia Therapeutics Ltd.
Phone: (44) 02380763400
Southampton Science Pk.
1 Venture Rd.
Chilworth, Southampton, SO16 7NP
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice